AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01277809 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Interaction
Description: Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program (Interpersonal Interaction Group; IIG). This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the WPG group. This interaction time will occur with the participant stationary, rather than walking with the researcher.
Study NCT01277809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Program
Description: Participants will walk five times per week, supervised by a licensed physiotherapist. Subjects will in general gradually increase their daily supervised walking time as tolerated to a maximum of 30 minutes once per day. The distance and number of minutes walked each time will be recorded. Interpersonal interaction will occur during the walking sessions, and will be similar in quality and quantity to that during the Interpersonal Interaction Group.
Study NCT02261103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole ER tablets
Study NCT02261103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole IR tablets
Study NCT02261103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching Pramipexole ER tablets
Study NCT02261103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Pramipexole IR tablets
Study NCT02261103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard high-fat breakfast
Study NCT00738166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Organic or conventional diet
Description: 12 days on fully controlled organic 1 diet, organic 2 diet and conventional diet
Study NCT00738166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet (organic or conventional)
Description: organic or conventional diet
Study NCT00738166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet (organic or conventional)
Description: organic or conventional diet
Study NCT04572568 — intervention group
Intervention type: OTHER
Intervention: Multi-disciplinary assessment
Description: 1. Comprehensive evaluation by multidisciplinary experts;~2. Preoperative multi-modal imaging examination was applied to determine the angioarchitecture, functional fiber bundle, and hemodynamics.
Study NCT01836848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: measuring cerebral perfusion by NIRS with ICG
Description: application of a bolus of 5mg indocyanine green (ICG) in 3ml saline 0,9% i.v. in 1 second and measuring the ICG turnover with the near-infrared-spectroscopy (NIRS)
Study NCT00203307 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olanzapine during first intervention period and placebo during second intervention period
Description: Olanzapine (5-10 mg) daily during first intervention period, then placebo(matching)druing second intervention period (after a washout period)
Study NCT00203307 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo during first intervention period, then olanzapine during second intervention period
Description: Placebo (matching) during first intervention period, then olanzapine (5-10 mg. daily) during the second intervention period (after a washout phase).
Study NCT02214823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.
Study NCT00859508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SyntheCel
Description: Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
Study NCT00859508 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Other FDA cleared dura replacements
Description: Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
Study NCT03901469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694
Description: PO QD
Study NCT03901469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: PO QD
Study NCT01267058 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' acellular pertussis vaccine
Description: Intramuscular, single dose
Study NCT01267058 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine
Description: Intramuscular, single dose
Study NCT03196037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: An 8-week Tai Chi intervention consisting of 75-minute group sessions held twice a week, over 8 weeks (i.e., total of 16 sessions).
Study NCT00650416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol Tablets 12.5 mg
Description: 12.5mg, single dose fasting
Study NCT00650416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coreg® Tablets 12.5 mg
Description: 12.5mg, single dose fasting
Study NCT02427438 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: A video with moving demonstration and verbal instruction of the exercise to strengthen low back
Study NCT02427438 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Handout
Description: A handout with a two dimensional picture and written instruction of the exercise to strengthen low back
Study NCT03684824 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Long luteal phase GnRH agonist protocol
Description: Pituitary suppression will be done using daily subcutaneous injection of triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the previous cycle
Study NCT03684824 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gonadotropins
Description: Controlled ovarian hyperstimulation will be done using daily intramuscular injection of highly purified Human Menopausal Gonadotrophins (Merional 75 IU/ml, IBSA, Switzerland), starting from day 2-3 of the stimulated cycle, total dose will be adjusted according to patient response
Study NCT03765424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultraosund of temporal, carotid and axillary arteries
Study NCT03336723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant
Description: Place a two piece zirconia dental implant on a healed ridge. At baseline, two month and crown placement take fluid samples with adsorbent paper in the per- implant crevicular fluid. At t2 and t3 repeat sample taken
Study NCT03336723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Implant
Description: Place a two piece zirconia dental implant on a healed ridge. At baseline, two month and crown placement take fluid samples with adsorbent paper in the per- implant crevicular fluid. At t2 and t3 repeat sample taken
Study NCT03672071 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ephedrine, Noradrenaline ,ephedrine+Noradrenaline)
Description: If a 20% decrease in any hemodynamic parameter compared to their baseline levels is sustained, necessary interventions will be performed. In the case of hypotension, for all groups
Study NCT01584271 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Natural Ear Comfort(TM), a botanical ear drops product
Description: Ear Comfort(TM): active ingredients - Thyme essential oil \& Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant.~Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units.~Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water.~Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin.
Study NCT04104113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Xiang Bei Yang Rong Tang
Description: Modified Xiang Bei Yang Rong Tang is a combination of 15 herbal components and it is available in granules form to be dissolved in hot water for consumption
Study NCT04104113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules contain 5% XBYRT, colourant, bitterant and 95% starch filler
Study NCT01734772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: multiple doses of dabigatran
Study NCT01584271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natural Ear Comfort(TM), a botanical ear drops product
Description: Ear Comfort(TM): active ingredients - Thyme essential oil \& Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant.~Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units.~Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water.~Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin.
Study NCT01001130 — intervention group
Intervention type: DRUG
Intervention: fluticasone furoate group
Description: patients who are administered fluticasone furoate at least once
Study NCT03126214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Description: Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with the Canadian Cardiovascular Society Guidelines for Atrial Fibrillation.
Study NCT03126214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulants
Description: Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with the Canadian Cardiovascular Society Guidelines for Atrial Fibrillation.
Study NCT01422083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: home stretching program
Description: A home stretching program (sleeper's stretch): 3 x 30 seconds, once a day for 6 weeks.
Study NCT03834207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the C3-Cloud IT system
Description: Patients who are recruited to the intervention arm will use the C3-Cloud system during the pilot study.
Study NCT00613223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib and Etoposide
Description: Vandetanib will be given orally once day. Swallow tablet with 240 ml of non-carbonated water. Initial dose is 100 mg/day for stratum 1 \& 200 mg/day for stratum 2. Etoposide will be taken by mouth in capsule form at a flat dose of 50 mg/day for 1st 21 days of 28-day cycle. You will not take etoposide for following 7 days of the cycle.
Study NCT04522778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Central Line Securement Device (Vest)
Description: The wearable central line securement device is a vest that has attachments for the central line to safely be secured to the body whether it is being used for infusion or unhooked. It also has a front flap, which protects the line from snagging on external objects.
Study NCT04522778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Securement Dressing
Description: All subjects will use sterile dressings throughout the trial as this is the standard of care for central line securement. Subjects randomized to the dressing arm will continue to use standard of care sterile dressing as the only form of central line securement.
Study NCT04522778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Securement Dressing
Description: All subjects will use sterile dressings throughout the trial as this is the standard of care for central line securement. Subjects randomized to the dressing arm will continue to use standard of care sterile dressing as the only form of central line securement.
Study NCT01246219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH treatment (Genotropin)
Description: 4 years treatment with GH
Study NCT01246219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1 year treatment with placebo followed by optional 3 years of GH treatment
Description: 1 year treatment with placebo followed by optional 3 years of GH treatment
Study NCT00160979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-treatment tumour oxygen measurements
Description: Pre-treatment tumour oxygen measurements
Study NCT01174485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exercise
Description: combined resistance and aerobic training
Study NCT00177372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone/misoprostol
Description: mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
Study NCT03935932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal delivery of heated and humidified air
Description: Subjects will receive nasal delivery of heated and humidified air (plus oxygen if needed) at 30 liters/minute from the Fisher and Paykel myAirvo2 heater/humidifier using an Optiflow nasal cannula.
Study NCT01845311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReZolve2 Scaffold
Study NCT01664897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT01664897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00107081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin and amoxicillin
Study NCT00107081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient management
Study NCT00107081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: i.v. antibiotics
Study NCT00107081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inpatient management
Study NCT02723513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Xenon-129
Description: Hyperpolarized Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.
Study NCT01027663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement
Description: Iron supplementation (325 mg of ferrous sulfate) once daily for the 2 month duration of the study.
Study NCT01649037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nor adrenaline and terlipressin
Description: IV bolus terlipressin at the dose of 0.5 to 1 mg every 6 hours with the maximum daily cumulative dose of 4 mg/day.~Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours in case of no response.\[ No response defined as MAP \< 10, or 4 hr Urine output \< 200 ml\] with maximum dose upto 3 mg/h.
Study NCT01649037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: step up terlipressin therapy
Description: IV bolus terlipressin starting at 1.5 mg every 6 hours with increase in dose by 0.5 mg/6 hours in case of no response \[\< 25% decrease in s.creatinine\] after every 48 hours. Maximum daily cumulative dose of 12 mg/day.
Study NCT00334971 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Follicle Aspiration
Description: Follicles will be aspirated using a transvaginal ultrasound guided needle.
Study NCT01734772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: medium dose dabigatran
Study NCT01734772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: loading dose of ticagrelor
Study NCT01537978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video gaming for enhanced function after spinal cord injury.
Description: Spinal cord injured indviduals will play Nintendo Wii sports games for an 8 week period.
Study NCT02778906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Administration of Abatacept s.c. 125mg/weekly according to the Label for Rheumatoid arthritis
Study NCT02778906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of the comparator s.c. weekly in comparable to verum
Study NCT04003961 — intervention group
Intervention type: OTHER
Intervention: STOP- BANG Questionnaire and Epworth sleepiness scale
Description: STOP- BANG Questionnaire and Epworth sleepiness scale will be filled in maximum 10 minutes
Study NCT03691142 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Interview of women with Hereditary Haemorrhagic Telangiectasia (HHT) during a consultation in the Reference Center for HHT or through a phone questionnaire about obstetric history, complications during pregnancy, delivery and neonatal outcomes.
Study NCT02151071 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EnLight
Description: The Lightpoint EnLight beta particle detector is an investigational non CE-marked medical device
Study NCT02151071 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LightPath
Description: The LightPath Imaging System is an investigational non CE-marked in vitro diagnostic device
Study NCT02010983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chromoendoscopy
Description: chromoendoscopy (lugol stain and virtual chromoendoscopy)
Study NCT00131547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: Dietary Counseling, use of a food diary and pedometer
Study NCT03618212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Skeletal MRI and pelvic and spinal MRI
Study NCT00264823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Memory Aids to take medications
Description: Experimental participants will receive an integrated intervention tailored to the communication and comprehension of the individual, and will include memory aid devices, education regarding side effects and other treatment aspects, and active community outreach. For those who fail to adhere using the basic intervention, a treatment cascade that increases in intensity will be implemented. Using 80% adherence as a target, the cascade will include involvement of family and significant others in prompting participants through use of beepers, cellphones, and for those who still fall short of 80% adherence, directly observed therapy.
Study NCT02196168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02196168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT01734772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: multiple doses of ticagrelor
Study NCT01734772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: single dose of dabigatran
Study NCT02034331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin iontophoresis
Description: For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
Study NCT02034331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Iontophoresis
Description: For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
Study NCT02034331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcholine Iontophoresis
Description: For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
Study NCT02034331 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heat application
Description: For the provocation with heat, an insulated thermal heat pack (\~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.